Clinical Trial

A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 15, 2021 (before its estimated May 2022 completion). Its status may not reflect the trial's current state.
Summary
This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma. In patients with one primary superficial or nodular basal cell carcinoma lesion with a diameter of 5-10mm (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-12-01.
Status change: Recruiting → Completed 2025-10-05
Trial Details
NCT Number NCT05157763
Lead Sponsor MediWound Ltd
Conditions Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
Enrollment 32 participants
Start Date 2021-06-30
Primary Completion 2022-05 (estimated)
Study Completion 2022-06 (estimated)
Updated on ClinicalTrials.gov 2021-12-15